CHRIS LOOSE, Ph.D.
Co-founder and Chief Scientific Officer
Chris is the Chief Scientific Officer and Co-founder of Frequency Therapeutics. Chris co-founded Semprus BioSciences and served as Chief Technology Officer through the company’s acquisition by Teleflex in 2012. He led the technology team in developing medical products with surface modifications designed to reduce infection and clotting, leading to FDA/CE Mark clearance. Prior to Semprus, Chris worked as a chemical engineer at Merck Research Labs. In 2011, he was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. Chris has also been named to the TR35, the 35 innovators under 35 most likely to impact technology, and the Boston Business Journal 40 under 40. He is currently an Associate Adjunct Professor of Urology in the Yale School of Medicine. Chris holds a Ph.D. in Chemical Engineering from MIT, where he studied under Robert Langer, Sc.D., and a BSE from Princeton University.